SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Summit Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026

$15.57+0.94 (+6.43%)

Close on Oct 19, 2026

Market cap: $12.12B
P/E (TTM): –
Dividend yield: –

Summit Therapeutics Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2019 2019-01-31	FY 2018 2018-01-31
Cash & Equivalents	225	105	71	649	72	35	28
Short-Term Investments	488	307	115	0	–	–	–
Cash & Short-Term Investments	713	413	186	649	72	35	28
Receivables	–	–	0	0.35	1.46	–	–
Prepaid Expenses & Other	6.54	11	2.62	1.50	7.16	–	–
Other Current Assets	–	–	0.18	0.49	1.20	–	–
Total Current Assets	720	424	190	657	97	–	–
Property, Plant & Equipment	1.06	0.25	0.20	0.91	0.69	–	–
Gross Property, Plant & Equipment	–	1.37	1.25	2.20	1.73	–	–
Accumulated Depreciation	–	-1.12	-1.04	-1.30	-1.04	–	–
Operating Lease Right-of-Use Assets	21	7.14	5.86	4.18	2.79	–	–
Goodwill	2.00	1.86	1.89	1.80	2.01	1.95	–
Intangible Assets	–	0	0	0	10	–	–
Other Long-Term Assets	7.21	2.55	4.32	0.58	0.17	–	–
Total Assets	751	436	203	664	113	–	–
Accounts Payable	20	4.64	2.67	0.36	4.37	–	–
Accrued Expenses	32	20	8.78	11	7.20	–	–
Current Portion of Leases	3.39	3.77	2.81	1.69	1.09	–	–
Deferred Revenue (Current)	–	–	–	0	7.94	–	–
Other Current Liabilities	2.28	1.80	0.72	0.66	0.90	–	–
Total Current Liabilities	73	42	20	39	26	–	–
Long-Term Debt	–	0	100	495	–	–	–
Long-Term Leases	18	3.45	3.29	2.76	1.69	–	–
Operating Lease Liabilities	21	7.22	6.10	4.45	2.78	–	–
Other Long-Term Liabilities	1.83	1.63	1.56	1.43	2.78	–	–
Total Liabilities	92	47	125	538	30	–	–
Total Debt	–	0	100	495	–	–	–
Preferred Stock	0	0	0	0	0	–	–
Common Stock	7.75	7.38	7.02	2.11	0.98	–	–
Additional Paid-In Capital	2,948	1,598	1,066	505	384	–	–
Retained Earnings	-2,294	-1,215	-993	-378	-300	–	–
Comprehensive Income & Other	-2.54	-2.29	-2.45	-1.89	-2.20	–	–
Shareholders' Equity	659	389	78	127	83	58	-3.59
Total Equity	659	389	78	127	83	58	-3.59
Total Liabilities & Equity	751	436	203	664	113	–	–
Shares Outstanding(shares)	775	738	702	211	98	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -206.1%

Financial strength

Current ratio: 6.96
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 404.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 19.23
Dividend yield: –